ES2051989T3 - Un procedimiento para la manufactura de una inmunotoxina para el tratamiento o profilaxis de una enfermedad autoinmune. - Google Patents

Un procedimiento para la manufactura de una inmunotoxina para el tratamiento o profilaxis de una enfermedad autoinmune.

Info

Publication number
ES2051989T3
ES2051989T3 ES89202588T ES89202588T ES2051989T3 ES 2051989 T3 ES2051989 T3 ES 2051989T3 ES 89202588 T ES89202588 T ES 89202588T ES 89202588 T ES89202588 T ES 89202588T ES 2051989 T3 ES2051989 T3 ES 2051989T3
Authority
ES
Spain
Prior art keywords
prophylaxis
treatment
immunotoxin
procedure
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89202588T
Other languages
English (en)
Inventor
Hermanus Antonius Mari Verheul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of ES2051989T3 publication Critical patent/ES2051989T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION CONCIERNE A UNA SUSTANCIA EPITOPE CITOTOXICA CONJUGADA PARA EL TRATAMIENTO DE PROFILAXIS DE ENFERMEDADESD AUTOINMUNES. LOS ENLACES CONJUGADOS ESPECIFICAMENTE PARA T-LINFOCITAS AUTOINMUNES Y ELIMINA LAS T-LINFOCITAS RESPONSABLES DE LAS ENFERMEDIADES AUNTOINMUNES.
ES89202588T 1988-10-21 1989-10-13 Un procedimiento para la manufactura de una inmunotoxina para el tratamiento o profilaxis de una enfermedad autoinmune. Expired - Lifetime ES2051989T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88202349 1988-10-21

Publications (1)

Publication Number Publication Date
ES2051989T3 true ES2051989T3 (es) 1994-07-01

Family

ID=8199870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89202588T Expired - Lifetime ES2051989T3 (es) 1988-10-21 1989-10-13 Un procedimiento para la manufactura de una inmunotoxina para el tratamiento o profilaxis de una enfermedad autoinmune.

Country Status (15)

Country Link
EP (1) EP0365087B1 (es)
JP (1) JP2807506B2 (es)
KR (1) KR0151851B1 (es)
AT (1) ATE78407T1 (es)
AU (1) AU625802B2 (es)
CA (1) CA2000999A1 (es)
DE (1) DE68902212T2 (es)
DK (1) DK523589A (es)
ES (1) ES2051989T3 (es)
FI (1) FI100305B (es)
GR (1) GR3006048T3 (es)
IE (1) IE61831B1 (es)
NZ (1) NZ231095A (es)
PT (1) PT92071B (es)
ZA (1) ZA897895B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
AU5132499A (en) 1998-08-11 2000-03-06 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for preventing anti-gal production in xenograft recipients
KR100346059B1 (ko) * 1999-12-30 2002-07-24 주식회사 효성 폴리에스테르 섬유의 제조방법
ES2370535T3 (es) * 2006-11-23 2011-12-19 Cadila Pharmaceuticals Limited Antagonista de poli-tlr.
EP3497452B1 (en) * 2016-08-12 2025-03-05 Immunowork, LLC Diagnosis, prevention, and/or treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.

Also Published As

Publication number Publication date
ATE78407T1 (de) 1992-08-15
EP0365087B1 (en) 1992-07-22
PT92071A (pt) 1990-04-30
CA2000999A1 (en) 1990-04-21
DE68902212T2 (de) 1993-05-27
ZA897895B (en) 1990-07-25
IE893324L (en) 1990-04-21
EP0365087A1 (en) 1990-04-25
PT92071B (pt) 1995-06-30
FI100305B (fi) 1997-11-14
AU625802B2 (en) 1992-07-16
AU4359589A (en) 1990-04-26
GR3006048T3 (es) 1993-06-21
KR0151851B1 (ko) 1998-10-15
JPH02169523A (ja) 1990-06-29
NZ231095A (en) 1992-03-26
FI895005A0 (fi) 1989-10-20
IE61831B1 (en) 1994-11-30
DK523589D0 (da) 1989-10-20
DE68902212D1 (de) 1992-08-27
DK523589A (da) 1990-04-22
KR900005996A (ko) 1990-05-07
JP2807506B2 (ja) 1998-10-08

Similar Documents

Publication Publication Date Title
CO4290353A1 (es) Agonistas de estrogeno
ES2067696T3 (es) Composiciones de liberacion sostenida para tratar la enfermedad periodontal.
AU8335291A (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
ES2194107T3 (es) Formulaciones farmaceuticas y dieteticas para la profilaxis y tratamiento de trastornos gastrointestinales.
ES2099977T3 (es) Composiciones de liberacion prolongada para tratar enfermedades periodontales.
ES2170102T3 (es) Aminociclohexilesteres y utilizacion de los mismos.
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
ES2196303T3 (es) Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias.
ES2097343T3 (es) Articulo absorbente curvado y conformado.
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
UY26182A1 (es) Prevención y tratamiento de la enfermedad amiloidogenica
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
ES2032016T3 (es) Un procedimiento para la produccion de las 13, 14-ceto-pgfs.
ES2061650T3 (es) Composiciones para el tratamiento de la enfermedad periodontal.
HN1998000174A (es) Combinacion eficaz para el tratamiento de la impotencia
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
ES2068705T3 (es) Tratamiento de la enfermedad neoplastica con interleuquina-10.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2066062T3 (es) Preparacion de liberacion sostenida para administracion al cerebro.
ES2089136T3 (es) Tratamiento de enfermedades inflamatorias con la ayuda de derivados 15-ceto-prostaglandinas.
ES2064613T3 (es) Produccion de agentes citotoxicos.
ES2082029T3 (es) Conjugados de acido difluoroglutamico con foliatos y antifoliatos para el tratamiento de enfermedades neoplasticas.
ES2078904T3 (es) Nuevos derivados de neplanocina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 365087

Country of ref document: ES